NASDAQ:PGNY Progyny (PGNY) Stock Price, News & Analysis $21.81 -0.27 (-1.22%) Closing price 04:00 PM EasternExtended Trading$21.72 -0.09 (-0.41%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Progyny Stock (NASDAQ:PGNY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Progyny alerts:Sign Up Key Stats Today's Range$21.71▼$22.2850-Day Range$19.82▼$23.8852-Week Range$13.39▼$33.85Volume1.08 million shsAverage Volume1.73 million shsMarket Capitalization$1.86 billionP/E Ratio37.60Dividend YieldN/APrice Target$23.64Consensus RatingHold Company OverviewProgyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.Read More… Remove Ads Progyny Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScorePGNY MarketRank™: Progyny scored higher than 31% of companies evaluated by MarketBeat, and ranked 813th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingProgyny has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 5 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageProgyny has only been the subject of 4 research reports in the past 90 days.Read more about Progyny's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth8.33% Earnings GrowthEarnings for Progyny are expected to grow by 8.33% in the coming year, from $0.60 to $0.65 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progyny is 37.60, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.47.Price to Earnings Ratio vs. SectorThe P/E ratio of Progyny is 37.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.73.Price to Earnings Growth RatioProgyny has a PEG Ratio of 2.39. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioProgyny has a P/B Ratio of 3.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Progyny's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.04% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Progyny has recently decreased by 36.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProgyny does not currently pay a dividend.Dividend GrowthProgyny does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.04% of the float of Progyny has been sold short.Short Interest Ratio / Days to CoverProgyny has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Progyny has recently decreased by 36.58%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.28 News SentimentProgyny has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Progyny this week, compared to 7 articles on an average week.Search InterestOnly 1 people have searched for PGNY on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Progyny to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Progyny insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Progyny is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Progyny's insider trading history. Receive PGNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter. Email Address PGNY Stock News HeadlinesProgyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of "Hold" from AnalystsApril 14 at 1:29 AM | americanbankingnews.comHealth Insurance Providers Stocks Q4 Teardown: Humana (NYSE:HUM) Vs The RestApril 10, 2025 | msn.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 15, 2025 | Porter & Company (Ad)The Broken Brown Egg and Progyny Announce the 2025 Awareness, Hope, and Activism Grant™ to Support BIPOC Individuals and Couples in Family BuildingApril 8, 2025 | globenewswire.comProgyny expands materna health support with doula servicesApril 1, 2025 | markets.businessinsider.comBTIG Upgrades Progyny (PGNY)April 1, 2025 | msn.comProgyny upgraded to Buy from Neutral at BTIGApril 1, 2025 | markets.businessinsider.com5PGNY : Analyst Expectations For Progyny's FutureMarch 31, 2025 | benzinga.comSee More Headlines PGNY Stock Analysis - Frequently Asked Questions How have PGNY shares performed this year? Progyny's stock was trading at $17.25 on January 1st, 2025. Since then, PGNY stock has increased by 26.4% and is now trading at $21.81. View the best growth stocks for 2025 here. How were Progyny's earnings last quarter? Progyny, Inc. (NASDAQ:PGNY) posted its quarterly earnings results on Tuesday, November, 12th. The company reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.37 by $0.26. The company's revenue for the quarter was up 2.0% on a year-over-year basis. Read the conference call transcript. When did Progyny IPO? Progyny (PGNY) raised $150 million in an initial public offering on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers. Who are Progyny's major shareholders? Top institutional investors of Progyny include Rhumbline Advisers (0.25%), GAMMA Investing LLC (0.14%), Leibman Financial Services Inc. (0.05%) and Yousif Capital Management LLC (0.03%). Insiders that own company stock include Tpg Gp A, Llc, Peter Anevski, Michael E Sturmer, Norman Payson, David J Schlanger, Mark S Livingston, Cheryl Scott and Kevin K Gordon. View institutional ownership trends. How do I buy shares of Progyny? Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Progyny own? Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN). Company Calendar Last Earnings11/12/2024Today4/15/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryHealthcare Current SymbolNASDAQ:PGNY CIK1551306 Webwww.progyny.com Phone212-888-3124FaxN/AEmployees310Year Founded2008Price Target and Rating Average Stock Price Target$23.64 High Stock Price Target$31.00 Low Stock Price Target$17.00 Potential Upside/Downside+8.6%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.57 Trailing P/E Ratio37.54 Forward P/E Ratio36.28 P/E Growth2.39Net Income$62.04 million Net Margins5.03% Pretax Margin7.18% Return on Equity11.36% Return on Assets7.87% Debt Debt-to-Equity RatioN/A Current Ratio2.62 Quick Ratio2.62 Sales & Book Value Annual Sales$1.17 billion Price / Sales1.59 Cash Flow$0.61 per share Price / Cash Flow35.58 Book Value$5.77 per share Price / Book3.77Miscellaneous Outstanding Shares85,413,000Free Float74,679,000Market Cap$1.86 billion OptionableOptionable Beta1.33 Social Links 20 Stocks to Sell NowGet This Free Report This page (NASDAQ:PGNY) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.